ADHD Medication Stimulants Nonstimulants Side Effects and Questions

Reviewd By Burton J. Tabaac, MD, FAHA"

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

ADHD medication can reduce inattention, hyperactivity and impulsivity for many children, teens and adults when it is prescribed and monitored by a qualified clinician. The main medication groups are stimulants and nonstimulants. Stimulants often work faster and are widely used. Nonstimulants may be used when stimulants do not fit, side effects are difficult, all day symptom coverage is needed or another health factor affects the choice.

Medication is one part of ADHD care. You may still need therapy, parent training, school support, work planning, sleep care, routines and skills training. Medication can make those supports easier to use, but it does not teach planning, organization, emotional repair or task systems by itself.

A safe medication plan starts with a clear diagnosis and a full health review. Your prescriber should ask about age, symptoms, daily impairment, heart history, blood pressure, sleep, appetite, weight, mood, anxiety, tics, substance use, current medicines, supplements and pregnancy status when relevant. For children, the prescriber may also track growth and school feedback.

You should never start, stop, raise, lower or share ADHD medication without prescriber guidance. Side effects, dose timing and medication response vary from person to person. A prescriber can help adjust the plan based on benefits, risks and daily function.

Fast answer for ADHD medication

ADHD medication options include stimulant medications and nonstimulant medications. Stimulants include methylphenidate based and amphetamine based medicines. Nonstimulants may include atomoxetine, guanfacine, clonidine and other options chosen by a prescriber. Some antidepressants are also used in selected cases, though approval status differs by country and medicine.

Stimulants often act faster than nonstimulants. Some people notice benefit the same day. Nonstimulants may take days or weeks to show fuller effect. The right choice depends on your symptoms, age, health history, side effects, treatment response and prescriber judgment.

Common medication questions include how long the medicine lasts, when to take it, what side effects to watch, how to track benefit, what to do during shortages and how medication interacts with anxiety, sleep, tics or substance risk. These questions should be discussed before treatment begins and again during follow up.

Medication response should be measured in real life. You may track fewer missing assignments, safer driving, better work completion, smoother mornings, less interrupting, fewer emotional blowups or better ability to start tasks. Symptom scores can help, but daily examples often show the most useful change.

Stimulants in plain language

Stimulant medication is a common ADHD treatment. It is called a stimulant because it increases activity in brain signaling systems linked with attention, motivation, executive function and impulse control. The two broad stimulant groups are methylphenidate based medicines and amphetamine based medicines.

Stimulants can improve attention, reduce impulsive behavior and lower hyperactivity for many people. A child may complete more classwork. A teen may manage assignments with less conflict. An adult may start tasks sooner, stay with work longer or interrupt less often.

Stimulants come in different forms. Some last a shorter part of the day. Some are designed to last longer. Some are tablets or capsules. Some formulations may be liquids, chewable forms or patches in certain settings. Availability depends on country, age, approval status and prescriber judgment.

Shorter acting medicines may allow more flexible timing. Longer acting medicines may reduce the need for school day or workday dosing. The tradeoffs can include appetite effects, sleep effects, afternoon symptom return or side effects that last longer. Your prescriber can explain the reason for a specific choice.

What stimulants may help

Stimulants may help with core ADHD symptoms such as distractibility, restlessness, impulsive speech, poor task persistence and difficulty completing work. They may also reduce some daily conflict when ADHD symptoms are driving the problem.

Medication benefit should be specific. “Feels better” is useful, but your prescriber also needs concrete markers. You can track task completion, school behavior, driving safety, work output, time loss, emotional reactions and side effects.

What stimulants cannot do alone

Stimulants do not replace skills. You may focus better and still need a calendar, written instructions, therapy, parent training, school support or work planning. Medication may help your brain access tools more reliably.

Stimulants also do not remove the need for sleep, nutrition and routines. Poor sleep can reduce attention and increase irritability even when medication helps.

Nonstimulants in plain language

Nonstimulant ADHD medication can help when stimulants are not a fit or when a prescriber sees a reason to choose a different path. Nonstimulants may be used for children, teens or adults depending on the medication, approval status and clinical situation.

Atomoxetine is one nonstimulant option. It affects norepinephrine, a brain chemical involved in attention and alertness. It may take longer than stimulants to show full benefit. Some people use it because it may give steady coverage through the day.

Guanfacine and clonidine are also used for ADHD in some cases. They affect alpha 2 adrenergic receptors, which can influence attention, impulsivity and emotional reactivity. They may be considered when hyperactivity, impulsivity, sleep issues, tics or aggression are part of the clinical picture, depending on the person and prescriber.

Some antidepressants may be prescribed in selected ADHD cases. Approval status differs, and this should be explained by the prescriber. These options may be considered when depression, anxiety, side effects or other factors affect medication choice.

When a nonstimulant may be discussed

A prescriber may discuss a nonstimulant when stimulants cause difficult side effects, worsen sleep, raise concern because of misuse risk, interact with another condition or fail to provide enough benefit. A nonstimulant may also be chosen when all day coverage is desired.

The decision should be based on your full clinical picture. Tell your prescriber about sleep, appetite, mood, anxiety, tics, substance use, blood pressure, heart symptoms and other medicines.

What to expect with nonstimulants

Nonstimulants may need more time before benefits are clear. You may need follow up to review dose, timing and side effects. Do not stop a nonstimulant suddenly unless your prescriber tells you to, especially with medicines that can affect blood pressure or heart rate.

Track the same real life outcomes you would track with stimulants. Look at attention, task completion, impulsivity, emotional reactions, sleep, appetite, school feedback, work output and side effects.

Side effects and monitoring

All ADHD medications can have side effects. Some are mild and fade. Some need dose changes, timing changes, a different medicine or urgent care. Your prescriber should explain what is common, what needs a call and what needs emergency help.

Common stimulant side effects can include lower appetite, weight loss, trouble sleeping, stomach upset, headache, irritability, anxiety, increased heart rate or increased blood pressure. Some people notice mood changes or rebound symptoms when medicine wears off.

Nonstimulant side effects depend on the medicine. They can include sleepiness, fatigue, stomach symptoms, appetite changes, dizziness, mood changes, blood pressure changes or dry mouth. Your prescriber should explain the specific side effects linked with the medicine chosen.

Children need growth and appetite monitoring. A prescriber may track height, weight, appetite, sleep, blood pressure, pulse, mood and school response. A child who loses weight, stops eating well or has poor sleep needs clinician review.

Adults may need monitoring for blood pressure, pulse, sleep, appetite, anxiety, mood, substance risk and work function. Older adults or people with heart symptoms may need extra review before medication decisions.

Side effects that need prompt medical attention

Contact a clinician quickly if you notice severe mood changes, new suicidal thoughts, hallucinations, mania symptoms, chest pain, fainting, severe allergic reaction, severe agitation, major appetite loss, marked weight loss or any symptom that feels unsafe.

For children younger than six, medication decisions need extra care. Recent U.S. Food and Drug Administration communication highlights higher risk of weight loss and other adverse reactions with extended release stimulants in this age group. Parents should discuss age, approval status and behavior therapy options with the child’s clinician.

How to track side effects

Use a simple record. Note medication name, dose, time taken, appetite, sleep, focus, mood, side effects and symptom return. For children, ask teachers for brief feedback on classwork, behavior and afternoon changes. For adults, track work output, time loss, task starts and side effects.

Bring this record to follow up. It helps your prescriber adjust dose, timing or medication choice.

Medication timing and daily routine

Medication timing can affect symptom control, appetite, sleep and daily planning. Your prescriber should explain when to take medication and what to do if a dose is missed. You should follow the prescription label and prescriber guidance.

Morning timing is common for many ADHD medicines, especially stimulants that can affect sleep when taken late. Some people need symptom coverage during school or work. Some also need support for homework, driving, evening chores or family routines.

Medication may wear off before the day is done. This can lead to afternoon or evening symptom return. You may notice irritability, hunger, fatigue, restlessness or poor focus as the medicine fades. Tell your prescriber if this pattern happens. The plan may need timing review.

Food can affect some medicines. Appetite loss is common with some stimulants, so your clinician may discuss breakfast before dosing, lunch planning or evening nutrition. Follow the specific guidance for the medication you are prescribed.

Building medication into routine

A fixed routine lowers missed doses. You may take medication after brushing teeth, with breakfast or next to another approved morning habit. Children may need adult supervision. Teens may need a transition plan as they take more responsibility.

Store medication safely. Many ADHD medications require careful handling because of misuse and diversion risk. Keep medication in a secure place, do not share it and follow local rules for refills and disposal.

Medication and driving

For teens and adults, ADHD symptoms can affect driving safety. Medication may help attention and impulse control during driving for some people. Timing matters if medication coverage ends before evening driving. Discuss this with your prescriber, especially for long commutes, late shifts or new teen drivers.

Shortages, access issues and prescriber follow up

ADHD medication access has been difficult for many people. Stimulant shortages and pharmacy supply problems can interrupt care. Adults have reported trouble filling prescriptions, and families may also face delays, partial fills or pharmacy changes.

If your medication is unavailable, contact your prescriber and pharmacist. Do not use medication from friends, buy pills outside a licensed pharmacy or change your dose on your own. Unregulated pills may be counterfeit, contain the wrong ingredient or contain dangerous substances.

Your prescriber may discuss other formulations, timing, dosage forms, pharmacies or medication options. The exact choice depends on your prescription, local rules and clinical history. Some controlled medicines have strict refill rules, so planning ahead matters.

Follow up is part of medication care. Early follow up may focus on benefit, side effects and dose timing. Later follow up may review growth for children, blood pressure, sleep, appetite, mood, school or work outcomes and ongoing need.

What to ask during a shortage

Ask practical questions.

  • Which pharmacies should I check
  • Are there other approved forms of this medicine
  • Is a different dose strength available
  • Should I wait, change timing or discuss another medication
  • What should I do if I miss several days
  • What symptoms should prompt urgent contact
  • How can I avoid unsafe sources

A shortage plan should come from your prescriber. It should account for your diagnosis, safety needs, work or school demands and side effect history.

Medication with anxiety, tics or sleep problems

ADHD medication decisions can change when anxiety, tics or sleep problems are present. These conditions do not automatically prevent medication, but they do need careful review.

Anxiety can overlap with ADHD. Worry can make attention worse, and ADHD can create anxiety through missed deadlines, conflict and repeated stress. Some people feel calmer when ADHD symptoms improve. Some people feel more anxious on a medication. Your prescriber should track both attention and anxiety.

Tics are sudden movements or sounds that can be hard to suppress. Some people with ADHD also have tic disorders. Medication choice may need extra monitoring. Tell your prescriber about current or past tics, family history and any change after starting medication.

Sleep problems can worsen attention, impulse control and mood. ADHD can also delay bedtime because of time drift, racing thoughts or trouble stopping activities. Some medications can affect sleep, especially when taken too late. Your prescriber may review timing, dose, formulation and sleep habits.

Depression and substance risk should also be discussed. Depression can affect concentration and motivation. Substance use can affect safety and medication choice. Honest information helps the clinician choose a safer plan.

Psychedelic research has added valuable attention to therapeutic setting, emotional processing and brain flexibility in mental health. Current ADHD medication decisions should still rely on approved treatments, clinician assessment and monitored care. A 2025 randomized trial of repeated low dose LSD in adults with ADHD found no better symptom reduction than placebo.

Questions before starting or changing medication

Before starting ADHD medication, ask direct questions. Bring a medication list, supplement list and health history. Include heart symptoms, fainting, blood pressure problems, sleep, appetite, anxiety, depression, tics, substance use and pregnancy status when relevant.

Useful questions include the following.

  • Which symptoms should this medication target
  • Why are you choosing this medication
  • How soon might benefits appear
  • How long should each dose last
  • What side effects are common
  • What side effects need urgent care
  • How will blood pressure, pulse, appetite, sleep and mood be monitored
  • How will growth be monitored for a child
  • What should school or work track
  • What should I do if a dose is missed
  • What should I do if the pharmacy cannot fill it
  • How often should follow up happen
  • What are the next options if this medicine does not fit

Before changing medication, ask why the change is being made. The reason may be limited benefit, side effects, symptom return, sleep problems, appetite loss, access problems or a new health factor. Clear reasoning helps you track the result.

If medication helps, continue follow up. If medication does not help, tell the prescriber with specific examples. ADHD medication plans often need adjustment before the right fit is found.

Conclusion

As you review ADHD medication options and current research limits, we at Rose Hill Life Sciences follow related questions through our work as a psychedelic research organization focused on the production and research of Psilocybe cubensis, with our role at the intersection of science and therapeutic integration reflected in our Massachusetts research work.

Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.

You May Also Like

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.